Therefore, based on ferric iron regulation and ferroptosis, drugs targeting G-quadruplexes should be reconsidered in clinical use in cancer patients with FANCJ deficiency (Odermatt et al., 2020). This evidence concerns the gene BRIP1 and cancer.